Could a biologic drug spare patients from repeat throat surgeries?
NCT ID NCT05309616
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested the drug Taltz (ixekizumab) in 10 people with idiopathic subglottic stenosis, a rare condition where scar tissue narrows the airway. The goal was to see if blocking IL-17A could slow scar formation and lengthen the time between needed surgeries. Participants received injections over several months, and researchers tracked how long they could avoid repeat procedures.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Taltz (ixekizumab)
- What this could lead to
- If it works, this could reduce or eliminate the need for repeat surgeries in people with idiopathic subglottic stenosis.
- What could go wrong
- This is a very small, early-phase trial with only 10 participants, so results may not apply to everyone. The drug also carries risks like infections and allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC SUBGLOTTIC STENOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yale New Haven Hospital
New Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.